A look to the future in non-alcoholic fatty liver disease: are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer? by Vincent, Rebecca K. et al.
R E V I EW AR T I C L E
A look to the future in non-alcoholic fatty liver disease:
Are glucagon-like peptide-1 analogues or sodium-glucose
co-transporter-2 inhibitors the answer?
Rebecca K. Vincent MSc1 | David M. Williams MSc2 | Marc Evans FRCP2
1Department of Gastroenterology, University
Hospital Llandough, Cardiff, UK
2Department of Diabetes and Endocrinology,
University Hospital Llandough, Cardiff, UK
Correspondence
Dr Rebecca K. Vincent, University Hospital
Llandough, Cardiff, CF64 2XX, UK.
Email: rebecca.vincent@doctors.org.uk
Abstract
The increasing prevalence of diabetes and non-alcoholic fatty liver disease (NAFLD) is a
growing public health concern associated with significant morbidity, mortality and eco-
nomic cost, particularly in those who progress to cirrhosis. Medical treatment is frequently
limited, with no specific licensed treatments currently available for people with NAFLD. Its
association with diabetes raises the possibility of shared mechanisms of disease progres-
sion and treatment. With the ever-growing interest in the non-glycaemic effects of diabe-
tes medications, studies and clinical trials have investigated hepatic outcomes associated
with the use of drug classes used for people with type 2 diabetes (T2D), such as
glucagon-like peptide-1 (GLP-1) analogues or sodium-glucose co-transporter-2 (SGLT2)
inhibitors. Studies exploring the use of GLP-1 analogues or SGLT2 inhibitors in people
with NAFLD have observed improved measures of hepatic inflammation, liver enzymes
and radiological features over short periods. However, these studies tend to have variable
study populations and inconsistent reported outcomes, limiting comparison between
drugs and drug classes. As these drugs appear to improve biomarkers of NAFLD, clinicians
should consider their use in patients with NAFLD and T2D. However, further evidence
with greater participant numbers and longer trial durations is required to support specific
licensing for people with NAFLD. Larger trials would allow reporting of major adverse
hepatic events, akin to cardiovascular and renal outcome trials, to be determined. This
would provide a more meaningful evaluation of the impact of these drugs in NAFLD. Nev-
ertheless, these drugs represent a future potential therapeutic avenue in this difficult-to-
treat population and may beget significant health and economic impacts.
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1 | INTRODUCTION
Non-alcohol related fatty liver disease (NAFLD) is a global health
concern. The prevalence of NAFLD is increasing, affecting 25% of
people globally,1,2 with a higher incidence in those with obesity
and/or diabetes.3 NAFLD is associated with a substantial health eco-
nomic impact, representing a financial burden of more than $100 bn
annually in the United States alone.1 Moreover, the personal impact
of NAFLD should not be underestimated, particularly given its associ-
ation with comorbidities including diabetes, cardiovascular disease
and the multi-system consequences of obesity leading to increased
morbidity. All-cause mortality is higher in those with NAFLD com-
pared with the general population,4 making it an important health
concern which needs to be addressed. Despite the burden of NAFLD,
there are few effective management strategies to offer patients.
2 | DIAGNOSIS OF NAFLD
Diagnosing NAFLD is challenging, as current disease definitions sug-
gest it is a diagnosis of exclusion, rather than a positive diagnosis.
The consensus is that a diagnosis of NAFLD can be made if there is
>5% of hepatic fat accumulation in the absence of other causes.2,5–7
This can make a positive diagnosis of NAFLD challenging because of
confounding factors, especially the presence of excess alcohol, and
the definition suggests a liver biopsy is required to quantify the
degree of fat. It is recognized that NAFLD is an inflammatory spec-
trum of disease, ranging from hepatic steatosis (often termed
NAFLD, which is not strictly so) to steatohepatitis, and ultimately
fibrosis and cirrhosis, which has its own sequelae.3,4 This spectrum
and the burden NAFLD places on society and the individual is illus-
trated in Figure 1.
A definition of NAFLD that is not solely based on histology is lac-
king, making the diagnosis and staging of NAFLD challenging. It is diffi-
cult to distinguish between simple hepatic steatosis and non-alcoholic
steatohepatitis (NASH) clinically, although both are an inflammatory
state, and it is difficult to predict who will progress to fibrosis and
cirrhosis, and who will remain in the earlier steatosis stage. Under-
standing the mechanism of disease progression is essential to target
individuals at greater risk of steatohepatitis to reduce morbidity whilst
ensuring cost-effective treatment can be identified and studied.8 There
are several non-invasive methods to identify individuals with NAFLD
(eg, NAFLD score, FIB-4 score, alanine transaminase [ALT]: aspartate
transaminase [AST] ratio, AST:platelet ratio). There are problems, how-
ever, with these scores as they are largely based on blood test results,
which have a poor predictive value,9 and liver function tests, which
poorly reflect liver damage.10 Abdominal imaging and transient
elastography can aid the diagnosis of steatosis and fibrosis.9 Bio-
markers such as cytokeratin-18, a protein released during hepatocyte
death which correlates with liver dysfunction, have been studied in
NAFLD.9,10 However, the cytokeratin-18 level is raised in any form of
liver damage and is therefore not specific to NAFLD. Adiponectin,
which has a role in lipid and glucose metabolism by influencing insulin
receptors, has also been suggested as a biomarker in NAFLD. In
dyslipidaemia and an insulin-resistant state, adiponectin levels are low
compared to controls and can be used to assess progression of hepatic
steatosis to NASH.10 Furthermore, leptin has been implicated due to
its role in appetite and body weight, and is associated with insulin
resistance (IR). Higher levels of leptin have been identified in individ-
uals with NALFD.10 However, these biomarkers are not routinely used
in clinical practice and further work is needed to identify meaningful
biomarkers. Diagnosis is often based on a combination of scoring sys-
tems, clinical history and risk factors such as diabetes, cardiovascular
disease, obesity and metabolic syndrome. Indeed, metabolic profiling
has been suggested as a useful tool when determining which patients
are more likely to progress to NASH and cirrhosis.11 Yet, despite know-
ing that certain patient groups are at risk of NAFLD, there is currently
no screening programme to identify those at greater risk of developing
steatohepatitis. Furthermore, non-invasive tests are frequently
unhelpful, often necessitating liver biopsy.5,6 However, there are signif-
icant risks and patient aversion associated with liver biopsy due to its
invasive nature. Nevertheless, if NASH can be proven, then the patient
may be suitable for novel treatments, off-label medication or participa-









F IGURE 1 A schematic linking the
disease spectrum of non-alcoholic fatty
liver disease and how as the disease
progresses it affects the individual and
society
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3 | PATHOPHYSIOLOGY OF NAFLD
The situation becomes increasingly complicated when considering the
pathophysiology of NAFLD because of its multifactorial nature and asso-
ciation with other comorbidities. Liver fat accumulation results from an
imbalance among fatty acid influx (adipose tissue lipolysis), hepatic de
novo lipogenesis and lipid disposition (fatty acid oxidation) and VLDL
secretion from the liver.12 Studies in humans have shown that adipose tis-
sue lipolysis, hepatic de novo lipogenesis and diet contribute to free fatty
acid (FFA) accumulation in the liver, with diet playing the smallest part.13
The progression of NAFLD involves an interplay between cellular stress
responses (lipotoxicity and increased oxidative stress)14 and hepatic lipid
flux, with varying degrees of cytotoxic potential, to which individual
patients respond differently,9 and inflammation. Additionally, the relation-
ship between gut and pancreatic-released hormones, gut microbiota, and
IR in muscle, adipose tissue and liver is implicated in the pathophysiol-
ogy.15,16 Although multifaceted, the key steps in the development and
progression of NAFLD are the development of IR,3,4 a high fat diet and
obesity.9 Obesity contributes to the pathophysiology by causing adipo-
cyte hypertrophy and hypoxia, leading to macrophage influx and pro-
inflammatory state.16 Obesity, however, is not the sole, or indeed key
contributory factor to the development and progression of NAFLD as it
can also be seen in lean individuals.13 IR which develops as part of the
inflammatory state causes hepatic steatosis, further dysregulation in adi-
pose tissue leading to increased FFAs17 and sensitization of the liver to
metabolic attacks.18,19 Hepatic lipotoxicity is caused by increased long-
chain fatty acids, ceramides and diacylglycerol stored within the liver,
causing the release of reactive oxygen species by the liver and contribut-
ing to inflammation and consequently hepatic fibrosis and hepatocyte
apoptosis. Furthermore, increasing hepatic steatosis renders the liver
resistant to insulin, exacerbating the situation.17 There is, however, a bidi-
rectional relationship between hepatic steatosis and IR, with each fuelling
each other.17 These processes ultimately lead to a pro-inflammatory state
and hepatocyte injury.9
As a result of their shared aetiology, NAFLD is intrinsically linked
with metabolic syndrome and type 2 diabetes (T2D).1 In fact, individ-
uals with T2D have a five times greater risk of NAFLD and progres-
sion to NASH than people without T2D.20 Yet, hepatic steatosis is
partly an adaptive and protective response in which lipotoxic FFAs
are stored as more stable components.21 However, with on-going
hepatic insult, and contributing factors, such as T2D and genetic
predisposition, this protective response is overwhelmed, leading to
hepatocyte damage and fibrosis.4 Hepatic IR is caused by pro-
inflammatory cytokines (tumour necrosis factor [TNF]α, interleukin
[IL]-6), endoplasmic reticulum stress, pro-inflammatory pathways,
such as the JUN and NF.kB pathway, and lipid metabolites, which fur-
ther exacerbate IR. Additionally, there is a complex relationship
between IR, glucagon and hepatic sensitivity to glucagon. Glucagon
exerts several direct hepatic effects including decreasing hepatic fat,
as demonstrated by studies investigating glucagon antagonists for
T2D.22 However, people with cirrhosis demonstrate a fasting
hyperglucagonaemia possibly due to failure of incretin hormones such
as glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) to suppress glucagon. This is associ-
ated with deranged liver enzymes and increased hepatic FFA flux due
to lipolysis in adipose tissue, complicating the picture.23 Interestingly,
GLP-1 analogues reduce glucagon secretion and hepatic fat accumula-
tion by blocking the endoplasmic reticulum stress response.24 Indeed,
the GLP-1 analogue liraglutide reduced postprandial triglyceride and
apolipoprotein B48 elevations in people with T2D after a fat-rich
meal.25 The effect of GLP-1 analogue use is discussed further below,
and the pathophysiology of NAFLD is summarized in Figure 2.
4 | TREATMENT CHALLENGES IN NAFLD
As the global burden of NAFLD is considerable, identifying a point in
the disease spectrum at which it becomes financially viable and effica-
cious to treat is crucial. Similar thought was followed in the manage-
ment of hepatitis C as the market flooded with several treatments, all
of which had varying success based on different viral genotypes, but
all were expensive. This needed to be evaluated in terms of which
treatments would provide the greatest benefit balanced against the
cost of the drug. Benefit could be in terms of, for example, positive
societal outcomes or health expenditure. Health technology assess-
ments also examined the best time to treat an individual with hepatitis
C. Given the burden NAFLD places on the economy, healthcare sys-
tem and the patient, further discussion to establish whether treating
individuals with hepatic steatosis or NASH is cost-effective or appro-
priate would be welcome.
Although there are several therapeutic targets which can be
exploited in the management of NAFLD, current UK guidelines only
recommend pioglitazone or vitamin E in those with advanced fibro-
sis.26 Thiazolidinediones, such as pioglitazone, increase adiponectin
release from ectopic fat, which reduces the release of pro-
inflammatory cytokines. Both rosiglitazone and pioglitazone were
studied, but concern surrounding the cardiovascular side effects asso-
ciated with their use limited progress. Nevertheless, pioglitazone
improves the histological features observed in NAFLD.27 However,
there remains a paucity of evidence to support the above guidance
and additional pharmacological options, or indeed surgical interven-
tions, in the management of NAFLD are needed.
Therapies which reduce body weight and/or IR affect NALFD
incidence or progression. One meta-analysis observed that metformin
use in people with T2D and NAFLD improved liver enzymes, body
mass index (BMI) and measures of IR but not histological measures,
such as hepatic steatosis, inflammation or fibrosis.28 A review
assessing statins in NAFLD reported that most studies demonstrated
improved lipid profiles and liver enzymes, although changes in fibrosis
measures were inconsistent.29 Interestingly, two recent meta-analyses
and systematic reviews demonstrated that bariatric surgery was effec-
tive in improving hepatic steatosis in the majority of patients, and
hepatic fibrosis in almost a third of participants.30,31 In experimental
studies, other treatments, for example, n-3 polyunsaturated fatty
acids,32 L-carnitine,33 limonoids34 and polyphenols,35 were shown to
reduce hepatic inflammation and liver enzymes.
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For most patients with NAFLD, however, the mainstay of treat-
ment is lifestyle modification, which is infrequently successful. This
highlights the need to identify effective alternatives for NAFLD along-
side lifestyle modification by targeting novel pathways.
5 | GLUCAGON-LIKE PEPTIDE-1
ANALOGUES
Glucagon-like peptide-1 analogues have developed considerably since
the isolation of the exendin-4 peptide from the Heloderma suspectum
(Gila Monster) lizard in 1992.36 The peptide GLP-1 is normally
secreted within minutes in response to oral glucose following cleavage
of the pre-proglucagon gene. The first action of GLP-1 to be charac-
terized was the “incretin effect”, whereby an oral glucose load leads
to greater pancreatic insulin secretion than an intravenous glucose
infusion at the same plasma glucose level. This is because GLP-1 aug-
ments insulin secretion and modulates glucagon secretion, being
secreted in response to oral rather than intravenous glucose.37 Impor-
tantly, people with T2D demonstrate a reduced incretin effect, with
reduced insulin secretion in response to the incretins GLP-1 and
GIP.38 Over the last 20 years therapy for T2D has progressed swiftly,
with the development of several injectable and oral GLP-1 analogues.
Key side effects associated with GLP-1 analogue use include nausea,
vomiting, diarrhoea, pancreatitis and local injection site reactions.
Whilst GLP-1 receptors are most prominently expressed in the
pancreas and central nervous system, they have also been observed in
the lungs, kidneys, heart, peripheral nervous system, gastrointestinal
tract, adipose tissue and liver. This implies that GLP-1 analogues may
have other important metabolic effects beyond glycaemic modulation.
Various trials have demonstrated significant improvements in impor-
tant metabolic outcomes associated with GLP-1 analogue use, includ-
ing reduced mortality, reduced major adverse cardiovascular events,39
reduced progression of renal disease,40 improved weight loss41 and
improved lipid profiles.42 Consequently, GLP-1 analogues broadly
improve metabolic health, particularly in people with T2D and an
impaired incretin hormone response.
6 | NAFLD AND GLP-1 ANALOGUES
As discussed above, drugs used to treat NAFLD generally aim to
reduce hepatic inflammation and oxidative stress to reduce progres-
sive fibrosis and cirrhotic liver disease. GLP-1 analogues have the
potential to improve hepatic outcomes in people with T2D, by
improving risk factors for NAFLD and direct hepatic mechanisms to
reduce inflammation and oxidative stress.
7 | NON-DIRECT HEPATIC EFFECTS OF
GLP-1
7.1 | Glycaemic and lipid control
The first licensed use of GLP-1 analogues was for exenatide in 2005 in
people with poorly controlled T2D, with five GLP-1 analogues (exenatide,
F IGURE 2 The pathophysiology of non-alcoholic fatty liver disease (NAFLD). The organs and tissues involved are listed, with the hormones
and inflammatory mediators released listed below. These affect lipid and insulin metabolism and contribute to an inflammatory state, leading to
hepatic cellular stress and the development of NAFLD. The green arrows represent a positive effect whereas the red arrows represent an
inhibitory effect. Therapeutic targets are included in purple. GLP-1, glucagon-like peptide-1; IL-6, interleukin-6; IL-12, interleukin-12; SGLT2,
sodium-glucose co-transporter-2; TZDs, thiazolidinediones; TNFα, tumour necrosis factor-α
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liraglutide, lixisenatide, dulaglutide and semaglutide) currently licensed for
T2D. These drugs are effective and associated with glycaemic control
(glycated haemoglobin [HbA1c] improvements of ~9−18 mmol/mol
(0.8%-1.6%).37 This is important, as changes in HbA1c are recognized as
an independent risk factor for the development and reversal of NAFLD in
people with T2D.19 Additionally, several trials investigating GLP-1 ana-
logues have observed improvements in markers of dyslipidaemia typically
associated with diabetes, such as lower LDL cholesterol and triglyceride
levels.43 Indeed, improved lipid profiles improve mortality and cardiovas-
cular outcomes, and decelerate the progression of NASH.44 This may be
a result of GLP-1 analogues improving adipose and hepatic tissue insulin
sensitivity. Indeed, “cross-talk” between adipose tissue and the liver may
be responsible for the reduced IR and improved glycaemic control associ-
ated with GLP-1 analogues by enhancing insulin's antilipolytic role and
reducing plasma FFAs.45
7.2 | Body weight
Glucagon-like peptide-1 analogues are a licensed therapy for obesity,
with liraglutide (Saxenda) approved for use in 2014 for people with a
BMI ≥30 kg/m2 or ≥27 kg/m2 and an obesity-related comorbidity.
GLP-1 analogues act peripherally to reduce gastric emptying and cen-
trally to stimulate hypothalamic neurones, which suppress appetite.
Liraglutide use in obesity is associated with an additional mean weight
loss of 5.9 kg over 56 weeks.46 Whilst not yet approved for weight
loss, other GLP-1 analogues in clinical use for T2D have shown prom-
ising weight loss effects.41 This may have significant clinical impact, as
almost 40% of people who attain a weight loss ≥1% total body weight
per year achieve NAFLD remission.47
8 | DIRECT EFFECTS OF GLP-1 ON THE
LIVER
Improved metabolic risk factor control would improve hepatic IR, halt-
ing or even reversing NASH. However, studies demonstrating GLP-1
receptors within the liver raise the possibility of direct hepatic action.
The latter is supported by studies observing reduced hepatic glucose
production and enhanced glucose uptake associated with intravenous
infusion of GLP-1 analogues.45
As detailed above, progression of fatty to fibrotic liver disease is
mediated by pro-inflammatory cytokines and inflammation, resulting in
hepatic and adipose IR exacerbating hepatic inflammation. Increased IR
impairs suppression of lipolysis, resulting in increased FFA levels and
hepatocyte damage. Interestingly, administration of GLP-1 analogues to
people with NASH improves hepatic and adipose insulin sensitivity,
enhances insulin-mediated suppression of lipolysis and lessens hepatic de
novo lipogenesis.43 Nevertheless, the confounding stimulation of insulin
secretion by GLP-1 analogues to overcome hepatic IR indirectly should
not be overlooked, and further studies evaluating this area are important.
As discussed, increased serum adiponectin level is the mechanism
associated with thiazolidinedione use in NASH, as higher adiponectin
correlates with improved insulin sensitivity and histological recovery
in hepatic steatosis.48 Similarly, liraglutide use in people with NASH
increased serum adiponectin and decreased serum leptin levels,
reducing the leptin:adiponectin ratio.43 This has important implica-
tions as adiponectin regulates hepatic fatty acid oxidation, reducing de
novo lipogenesis.49 Moreover, elevated GLP-1 levels in vagotomized
mice directly prevented hepatic VLDL overproduction and improved
IR measures.50 This occurs because GLP-1 analogues such as
exendin-4 increase peroxisome proliferator-activated receptor-α
(PPARα) expression, which is typically reduced in people with NAFLD,
stimulating FFA oxidation.51 Moreover, GLP-1 analogues reduce fatty
acid-related hepatocyte apoptosis by reducing endoplasmic reticulum-
mediated cell death and hepatic FFA accumulation.52
Glucagon-like peptide-1 analogues also appear to improve
hepatic gluconeogenesis and IR. In dogs, exenatide increased hepatic
glucose turnover by ~30% because of increased whole-body glucose
disposal and hepatic glucose uptake in hyperglycaemic or euglycaemic
conditions.53 This is the mechanism highlighted by pre-clinical studies
to explain improvements in glycaemic control associated with GLP-1
analogue use.54 Therefore, GLP-1 analogues may break the inflamma-
tory cycle associated with fatty liver disease to limit the development
of advanced fibrotic disease, thereby supporting the role of the liver
in moderating glycaemic control.49
9 | POTENTIAL ROLE OF MULTI-
AGONISTS IN NAFLD
Multi-agonists of GLP-1, GIP and/or glucagon receptor have been
developed and investigated for treatment of diabetes and obesity.
Co-agonism of the glucagon receptor with incretin hormone agonists
may seem counterintuitive due to their opposing glycaemic effects,
especially because a function of GLP-1 is to suppress pancreatic glu-
cagon release.55 However, stimulation of the glucagon receptor has
several non-glycaemic effects such as enhancing energy expenditure,
hepatic lipid oxidation and improving weight loss amongst other fac-
tors.56 Indeed, reduced glucagon receptor signalling increases hepatic
fat accumulation,57 and use of glucagon antagonists in people with
T2D increases hepatic fat.22 One trial observed that people with T2D
and NAFLD had higher fasting glucagon levels than controls without
NAFLD.58 Some hypothesize that reduced hepatic glucagon receptor
signalling in NAFLD results in a pancreatic feedback mechanism,
resulting in augmented compensatory glucagon secretion.59
The hepatic benefits associated with dual GLP-1/glucagon receptor
agonism appear to have direct and indirect mechanisms.60 Hepatic gluca-
gon receptor signalling reduces hepatic fat and improves mitochondrial
turnover, whilst enhanced GLP-1 signalling reduces food intake and body
weight and improves glycaemic control.61 Co-agonist treatment in mice
significantly improves obesity, diabetes and measures of hepatic inflam-
mation and fibrosis.62 Thus, the potentially harmful changes in glycaemic
control associated with glucagon receptor agonism are curtailed by
enhanced GLP-1 signalling, whilst supporting further hepatic benefits
through the mechanisms discussed previously.
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10 | EVIDENCE FOR GLP-1 ANALOGUES
AND MULTI-AGONISTS IN LIVER DISEASE
10.1 | Exenatide
One trial explored the effect of exenatide on ectopic fat stores,
observing significant reductions in epicardial and liver fat content over
26 weeks.63 Other studies have demonstrated additional improve-
ments in glycaemic control, body weight, triglycerides and hepatic
enzymes in people treated with exenatide and insulin.64,65 Indeed,
exenatide use supported histological resolution of NASH in one pilot
study.66 However, most of these trials had only short-term follow-up
and lacked a placebo-controlled group.63,64
10.2 | Liraglutide
The LEAN-J pilot study67 and LEAN trial68 evaluated the effect of
liraglutide in the treatment of biopsy-proven NASH. Liraglutide use
was associated with improved weight loss, visceral fat content,
hepatic enzymes and hepatic inflammation on histology. Whilst
encouraging, it would be useful to know the longer-term impact on
NASH outcomes, as the trial extended to 48 weeks. Moreover, partic-
ipant numbers were small, with only 71 participants combined. How-
ever, a strength of the LEAN study was that it defined NASH
resolution histologically and used two independent pathologists, fea-
tures lacking in most trials to date. The CGH-LiNASH trial is an ongo-
ing study to compare changes in body weight, hepatic fat content and
liver enzymes in participants with NASH receiving liraglutide 0.6 to
3.0 mg or bariatric surgery.69
10.3 | Lixisenatide
We are unaware of completed or ongoing prospective trials investi-
gating lixisenatide in people with NAFLD. A previous systematic
review of randomized controlled trials using lixisenatide for people
with T2D concluded that its use improved the likelihood of ALT nor-
malization in obese patients over 29 weeks, but did not significantly
affect serum AST, alkaline phosphatase or bilirubin.70 However, inter-
pretation of this review should be cautious as it included trials which
did not aim to determine the impact of lixisenatide in NAFLD.
Included trials recruited people with T2D (with or without NAFLD)
and excluded those with severe liver disease.
10.4 | Dulaglutide
We are not aware of published trial evidence investigating dulaglutide
in NASH. The D-LIFT trial aimed to investigate the effect of
dulaglutide 0.75 to 1.5 mg once weekly for 24 weeks on hepatic fat
measurements in people with T2D using magnetic resonance imaging-
derived proton density fat fraction. The study enrolled 60 participants
and concluded in February 2020.71 We look forward to the publica-
tion of the results from this trial.
10.5 | Semaglutide
The SEMA-NASH trial recently completed in March 2020 investigated
semaglutide 0.1 to 0.4 mg daily in people with NASH over
72 weeks.72 Preliminary results indicate good outcomes, with NASH
resolution in most participants receiving the highest dose of
semaglutide.73 This study is a dedicated fatty liver disease trial evalu-
ating semaglutide in 320 participants with NASH with or without
T2D. The trial results may change the way we view NASH as a sepa-
rate disease entity to T2D, although with overlapping pathophysiolog-
ical mechanisms. Of course, should this trial demonstrate superiority,
there would be a case for major treatment changes in in this cohort.
Completed trials investigating GLP-1 analogues in NASH are shown in
Table 1.
10.6 | Multi-agonists
Evidence supporting the use of dual/triple agonists in liver disease is
largely preclinical. One early study found that use of a dual GLP-1/
glucagon receptor agonist in mice resulted in significant weight loss,
improved lipid metabolism and hepatic steatosis.74 Subsequent stud-
ies have demonstrated that dual agonists are associated with
improved hepatic histopathological changes in rodents.75,76 Interest-
ingly, a recent study investigated the effect of individual or combina-
tion administration of GLP-1, GIP and glucagon receptor agonists in
mice. The study observed that both dual GLP-1/glucagon receptor
agonists and triple GLP-1/GIP/glucagon receptor agonists resulted in
greater histological improvements in NAFLD disease activity com-
pared with liraglutide. Moreover, GIP or glucagon receptor analogues
alone did not influence liver lipids or histology.77
Whilst dual GLP-1/GIP receptor agonists have shown promise in
several features of metabolic syndrome,78 few focused studies have
investigated their role in people with liver disease. In a post hoc analy-
sis of a phase II trial for diabetes, people with T2D administered the
dual GLP-1/GIP receptor agonist tirzepatide showed improvements in
biomarkers of NASH, including liver enzymes and adiponectin.79
However, an unknown proportion of participants had NASH, and
hepatic fat was not measured, limiting the analysis. Similar results
have been observed with the use of triple agonists in mice, with
improved body weight and steatohepatitis.80 Whilst preclinical evi-
dence is encouraging, focused human trials exploring multi-agonists
would be welcomed.
10.7 | Dipeptidyl peptidase-4 inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibitor use in T2D is common, with
several drugs in this class used in clinical practice, such as saxagliptin,
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sitagliptin, linagliptin and vildagliptin. Side effects include gastrointes-
tinal disturbance, nasopharyngitis and skin lesions.81 The DPP-4
enzyme degrades GLP-1 and GIP and therefore DPP-4 inhibitor use
prolongs the action of endogenous incretins. Given the results associ-
ated with GLP-1 analogues in this cohort, DPP-4 inhibitors may
improve NAFLD outcomes also. However, DPP-4 inhibitor use in T2D
is neutral with respect to body weight changes and cardiovascular
protection.81 Nevertheless, DPP-4 inhibitor use in animal models with
fatty liver disease has demonstrated positive results, with reduced
proinflammatory measures such as TNFα, IL-6, adipose tissue inflam-
mation and hepatic steatosis.82 However, results of DPP-4 inhibition
in people with NAFLD have provided mixed results.
Saxagliptin improved measures of IR, inflammatory markers
and liver enzymes in people with NAFLD and T2D.83 Similarly,
addition of saxagliptin and dapagliflozin to metformin in people
with T2D significantly reduced liver and adipose fat content, and
improved liver enzymes.84 Vildagliptin was found to improve liver
enzymes and reduced fasting hepatic triglycerides by 27% in peo-
ple with T2D over 6 months.85 This was supported by a subse-
quent trial which observed improved fatty liver grading on
ultrasonography, improved liver enzymes and lipids, and reduced
body weight associated with vildagliptin use in people with
NAFLD.86 Whilst linagliptin has shown promise in rodent models
of NAFLD,87 we are not aware of any completed human trials eval-
uating its use in NAFLD. Results from trials investigating the effect
of sitaglipitin on NAFLD are mixed. One trial found significantly
greater reductions in hepatic steatosis and NAFLD activity score
associated with sitagliptin in people with NASH over 1 year.88 Sim-
ilarly, sitagliptin use resulted in greater hepatic and total body fat
content reductions than glimepiride in people with T2D despite
similar improvements in glycaemic control.89 However, other stud-
ies observe sitagliptin was not associated with improved fibrosis
score, NAFLD activity score, liver enzymes, serum adiponectin or
lipid profiles over 24 weeks in people with biopsy-proven NASH.90
Similarly, sitagliptin did not improve liver fat content, liver
enzymes or lipids in people with NAFLD and T2D or prediabetes
over 24 weeks.91
Despite these hopeful results, randomized controlled trials with
longer follow-up and larger participant numbers are lacking. However,
DPP-4 inhibitors appear to be safe in NAFLD, although the clinical
benefit of these medications in the treatment of NAFLD is debated.
10.8 | Sodium-glucose co-transporter-2 inhibitors
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are licensed for
the treatment of T2D. The commonest side effects associated with
their use are an increased frequency of genital and urinary tract infec-
tions and, rarely, diabetic ketoacidosis. These drugs inhibit SGLT2 in
the proximal convoluted tubule, causing a glucose-mediated osmotic
diuresis and natriuresis to improve glycaemia, weight loss and blood
pressure.92 Thus, these drugs improve all-cause mortality and cardio-
vascular outcomes and reduce progression of chronic renal disease in
people with diabetes.40,92 There is therefore potential to improve out-
comes in people with NAFLD. Moreover, as these drugs are already
used for people with T2D, introducing them for new indications such
as NAFLD is a relatively quick and inexpensive process compared with
producing new therapies, if there is benefit associated with their use.
In contrast to the GLP-1 receptor, SGLT2 expression is limited to the
proximal convoluted tubule and glucagon-secreting pancreatic α
cells.93 This implies the mechanisms by which SGLT2 inhibitors affect
liver outcomes are indirect and different from GLP-1 analogues. This
has been observed in the context of cardiovascular outcomes, with
an anti-inflammatory role of GLP-1 analogues and improved
haemodynamic effects associated with SGLT2 inhibitor use, beyond
the impact of these drugs on glycaemic control.
Firstly, use of SGLT2 inhibitors is associated with weight loss
~3 kg, with a preferential reduction in visceral fat rather than water
loss after 4 weeks of treatment.41 Secondly, these drugs are also asso-
ciated with HbA1c improvements of ~5 to 11 mmol/mol (0.5%-1.0%),
improving hepatic outcomes.19 Thirdly, SGLT2 inhibitor use is associ-
ated with a shift in lipid metabolism to reduce serum triglycerides and
increase LDL levels.94 The shift in lipid metabolism is probably a result
of a reversal of the high insulin:glucagon ratio frequently seen in peo-
ple with T2D. This occurs as a result of SGLT2 inhibitor-mediated
glycaemic improvements causing a relative drop in serum insulin, and
blockade of SGLT2 in the pancreatic α cell, resulting in increased glu-
cagon secretion.93,95 The reduced insulin:glucagon ratio promotes
a shift from hepatic carbohydrate to fatty acid metabolism to
reduce liver triglyceride content and β-oxidation of hepatic FFAs,
with subsequent ketone formation potentially causing euglycaemic
ketoacidosis.95 Certainly, glucagon has an important role in NAFLD
development, and the hormonal shift in insulin and glucagon induced
by SGLT2 inhibitors may mediate NAFLD remission.96 Reduced gluca-
gon receptor expression or use of glucagon receptor antagonists
increases hepatic fat levels.22,57
A recent systematic review of trials in people with T2D and
NAFLD treated with SGLT2 inhibitors observed consistent improve-
ments in NAFLD outcomes. These included improved liver enzymes,
liver fat content, measures of liver fibrosis and risk factors including
BMI, HbA1c and lipids.97
11 | EVIDENCE FOR SGLT2 INHIBITORS IN
LIVER DISEASE
11.1 | Dapagliflozin
One non-randomized trial found that dapagliflozin use was associated
with reduced BMI, body fat mass, reduced liver enzymes and
increased serum adiponectin.98 However, the study was limited by a
lack of data regarding hepatic fat changes during the study. The DEAN
study is an ongoing phase III trial aiming to recruit 100 participants
with NASH and T2D to investigate the impact of dapagliflozin 10 mg
daily on histological liver changes over 12 months. The study is
expected to be completed in November 2021.99
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Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; γGGT, gamma-glutamyl transpeptidase; HbA1c, glycated
haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LFC, liver fat content; NAFLD, non-alcoholic fatty liver disease; NASH, non-
alcoholic steatohepatitis; T2D, type 2 diabetes.
aResults presented as absolute values as no control group in study.
bResults presented after adjustment for control or placebo group.
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11.2 | Empagliflozin
The E-LIFT trial observed greater improvements in liver fat reduc-
tion compared to control and improvements in several liver enzymes
with empagliflozin use.100 The recently published EmLiFa trial
supported these results with improvements in liver fat and increased
likelihood of NAFLD resolution associated with empagliflozin use in
people with recently diagnosed and well-controlled T2D.101 This
was a relatively well-designed study and was placebo-controlled,
with uric acid and adiponectin levels collected to explain the find-
ings. However, it lacked follow-up (24 weeks) and included only
84 participants. An analysis of data pooled from five trials investi-
gating empagliflozin use reported improved liver enzymes with
empagliflozin use, with greater reductions in those with higher base-
line ALT levels.102
There are ongoing studies investigating empagliflozin. One study
aims to recruit 60 participants with NASH and T2D to determine liver
fat changes associated with empagliflozin alone and in combination
with pioglitazone over 6 months.103 Another trial aims to determine
whether empagliflozin improves hepatic fat measurements in 12 to
17-year-old obese participants with NAFLD over 26 weeks.104 We
anticipate the results of these trials with great interest.
11.3 | Canagliflozin
One small study investigating canagliflozin in participants with NAFLD
observed improved histopathological signs of NAFLD in all cases after
24 weeks.105 Further studies have since observed improvements in
liver enzymes, liver fat content and triglycerides associated with
canagliflozin.106–108 Each of these studies is limited by small partici-
pant numbers (n = 5-35) and a lack of control group and therefore,
whilst indicative of a benefit in NAFLD, larger controlled trials with
longer follow-up are needed to support canagliflozin use in NAFLD.
We are not aware of ongoing trials using canagliflozin in NAFLD at
the time of writing.
11.4 | Other SGLT2 inhibitors
Two Japanese studies investigating ipragliflozin in NAFLD participants
with T2D observed improvements in HbA1c, body weight, liver
enzymes, visceral fat and hepatic steatosis.110,111 A recent Korean
study observed that ipragliflozin use was associated with improved
hepatic and visceral fat content and liver enzymes.112 These trials are
presented in Table 2.
In one randomized-controlled trial, participants randomized to
luseogliflozin had greater improvements in liver:spleen ratio and vis-
ceral fat area than participants receiving metformin.113 A subsequent
trial found measures of hepatic fat and enzymes improved with
luseogliflozin, although markers of fibrosis were unchanged.114
An ongoing trial aims to compare the effect of tofogliflozin
20 mg daily and pioglitazone 15 to 30 mg daily, alone and in
combination, on changes in hepatic fat content over a 48-week
trial.115 Completed trials investigating SGLT2 inhibitors in NAFLD
are presented in Table 2.
12 | CONCLUSIONS
There is an important population burden of NAFLD, which is likely to
increase with the rising prevalence of T2D. Whilst most people with
NAFLD may be asymptomatic, a substantial proportion of these people
develop progressive liver disease, resulting in cirrhosis or hepatocellular
carcinoma. This is associated with significant personal and economic cost.
Nevertheless, there is a lack of current evidence-supported treatment
available and no licensed therapies for NAFLD exist. However, guidance
supports use of pioglitazone in NAFLD, which corroborates the potential
for other diabetes therapies to treat such patients.
Trials to date would support the use of GLP-1 analogues or
SGLT2 inhibitors in people with NAFLD and T2D. With ongoing
research, further licensing and guidance may be extended to include
these drugs specifically for the treatment of NAFLD. Novel drugs clas-
ses, including GLP-1/GIP/glucagon receptor dual or triple agonists,
are being investigated and show great promise. Variable reported out-
come measures in clinical trials challenge comparison between drugs
and drug classes.
Nevertheless, trials evaluating the impact of SGLT2 inhibitors and
GLP-1 analogues in NAFLD lack data surrounding major adverse
hepatic events such as development of liver cirrhosis or hepatocellular
carcinoma. This contrasts with cardiovascular and renal outcome stud-
ies which report on major events affecting these systems. This is likely
a consequence of the relatively limited follow-up and would be of
major interest given the burden that these stages of liver disease rep-
resent. Larger studies with greater patient numbers and duration with
more consistently reported outcomes including hepatic fat changes
would be welcome.
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